Czech et al. used mouse models of allogeneic hematopoietic stem cell transplantation (allo-HCT) to investigate the role of lipocalin-2 (LCN2) as a newfound regulator of intestinal graft-versus-host disease (GVHD). Administration of recombinant LCN2 protein after disease onset prevented GVHD progression, suggesting that it may play a role in reversing tissue damage that has already begun.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.it.2024.03.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identification of Novel LCN2 Inhibitors Based on Construction of Pharmacophore Models and Screening of Marine Compound Libraries by Fragment Design.
Mar Drugs
January 2025
The Marine Biomedical Research Institute of Guangdong Zhanjiang, School of Ocean and Tropical Medicine, Guangdong Medical University, Zhanjiang 524023, China.
LCN2, a member of the lipocalin family, is associated with various tumors and inflammatory conditions. Despite the availability of known inhibitors, none have been approved for clinical use. In this study, marine compounds were screened for their ability to inhibit LCN2 using pharmacophore models.
View Article and Find Full Text PDFThe lipocalin saga: Insights into its role in cancer-associated cachexia.
Biochim Biophys Acta Mol Basis Dis
January 2025
National Forensic Sciences University, Gandhinagar 382007, Gujarat, India. Electronic address:
Cancer-associated cachexia (CAC) is a debilitating condition, observed in patients with advanced stages of cancer. It is marked by ongoing weight loss, weakness, and nutritional impairment. Lower tolerance of chemotherapeutic agents and radiation therapy makes it difficult to treat CAC.
View Article and Find Full Text PDFSirt1 blocks nucleus pulposus and macrophages crosstalk by inhibiting RelA/Lipocalin 2 axis.
J Orthop Translat
January 2025
Department of Orthopaedics, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Rd, Nanjing, 210029, China.
Article Synopsis
- Intervertebral disc degeneration (IVDD) is a major cause of low back pain, and while Sirt1 agonists show promise in protecting intervertebral discs, the exact mechanisms involved are not fully understood.
- The study utilized various models to investigate the role of Sirt1 in disc cell inflammation and homeostasis, revealing that Sirt1 overexpression can inhibit inflammation and matrix degradation in degenerating discs.
- Findings suggest that Sirt1 regulates inflammation by negatively impacting Lipocalin 2, signaling a potential pathway for developing treatments aimed at preventing IVDD progression.
Prevalence of Acute Kidney Injury (AKI) in Children with Severe Malaria Using a Novel Biomarker: Serum Neutrophil Gelatinase Associated Lipocalin (NGAL) in Enugu.
West Afr J Med
August 2024
Department of Paediatrics, College of Medicine UNEC, Enugu, Enugu State, Nigeria Tel: +234 8034710392, Email:
Objectives: This study aims to determine the prevalence of Acute Kidney Injury (AKI) among children with severe malaria who present to the emergency room, using serum creatinine and NGAL levels as biomarkers. It also aims to ascertain which biomarker (serum creatinine and NGAL) detects AKI earliest, especially at day 0. The study is also aims to determine the relationship between parasite density and levels of serum NGAL.
View Article and Find Full Text PDFVillin-1 regulates ferroptosis in colorectal cancer progression.
FEBS J
December 2024
Department of Research, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide. Despite extensive research, the mechanistic underpinnings driving CRC progression remain largely unknown. As a fundamental component of the brush border cytoskeleton, villin-1 (VIL1) acts as a marker for intestinal cell differentiation and maturation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!